Last October, Oridion received a warning letter from the FDA about procedures to ensure that its products conform to specified requirements. Although the company says it made efforts to correct the issues, the bar occurred last week. Fourth-quarter growth will be “minimal” and full-year revenue is expected to increase 17 percent instead of the previously expected 20 percent, the company said.
Related Articles on Medical Devices:
KSpine Raises $2.5M for Spinal Implant to Treat Scoliosis
FDA Targets Risks From Reused Medical Devices
Novus Scientific Receives New U.S. Patent for Mesh Implant
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.